Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11771683 Dosing regimen for a selective S1P

Patent 11771683 was granted and assigned to Actelion on October, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Andreas Krause

Matthias Hoch

Jasper Dingemanse

Date of Patent

October 3, 2023

Patent Application Number

17090756

Date Filed

November 5, 2020

Patent Citations

US Patent 8273779 Thiazolidin 4-one derivatives

US Patent RE43728 Thiazolidin-4-one derivatives

US Patent RE43833 Thiazolidin-4-one derivatives

US Patent 8492441 Dosage regimen of an S1P receptor agonist

US Patent 8524752 Thiazolidin-4-one derivatives

US Patent 8785484 Dosing regimen for a selective S1P1 receptor agonist

US Patent RE45174 Thiazolidin-4-one derivatives

US Patent 8912340 Process for the preparation of 2-imino-thiazolidin-4-one derivatives

...

Patent Primary Examiner

Umamaheswari Ramachandran

CPC Code

...

Patent abstract

The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11771683 Dosing regimen for a selective S1P

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.